Wockhardt shares gained nearly 4.00% on Wednesday following the company's announcement of filing a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222 on January 5. This regulatory milestone represents a significant development in the pharmaceutical company's drug development pipeline and marks the first New Chemical Entity discovered and developed in India to be submitted for pan-European marketing authorisation.

Stock Performance and Market Response

Shares of Wockhardt are trading 3.20% higher at ₹1,514.00, reflecting positive investor sentiment following the regulatory filing announcement. The stock has gained 15.00% over the past month, demonstrating sustained momentum in the pharmaceutical company's market performance.

Regulatory Submission and Accelerated Assessment

The company filed the marketing application with the EMA, which serves as the regulatory authority for pharmaceutical products across 27 European Union member states and three European Economic Area countries. The EMA has informed Wockhardt that WCK 5222 is eligible for Accelerated Assessment, allowing for an abridged review timeline that reflects the unmet medical need addressed by the product.

Management Commentary and Market Potential

In an interaction with CNBC-TV18, Wockhardt's Habil Khorakiwala indicated that European approval for Zaynich is expected by July and August, with the market size in the continent estimated between $400.00 million to $500.00 million. Khorakiwala also stated that Zaynich's financial impact will begin reflecting in the balance sheet by financial year 2028.

About Zaynich® (WCK 5222)

Zaynich® is a novel, proprietary antibiotic combining Zidebactam and Cefepime to combat multi-drug resistant Gram-negative infections. The drug recently completed a global, pivotal Phase III clinical trial supporting its marketing authorization across international markets. The New Drug Application has been filed and accepted by the US FDA under fast-track review, while applications have also been submitted to Indian regulatory authorities.

Based on comprehensive clinical and regulatory data included in the application, Wockhardt expects WCK 5222 approval for treatment of resistant Gram-negative infections across all countries under EMA jurisdiction. The priority review status underscores the global urgency to make effective treatment options available for patients suffering from life-threatening multi-drug resistant infections.

Wockhardt Limited has received an upgraded ESG (Environmental, Social, and Governance) rating of 73 (Excellent) for 2025 from ESG Risk Assessments & Insights Limited, a SEBI-registered ESG rating provider. This represents a significant improvement from the company's previous ESG rating of 67.3 received for Financial Year 2024-25. The pharmaceutical company disclosed this latest information to stock exchanges on January 1, 2026, in compliance with regulatory requirements.

Latest ESG Rating Assessment

The new rating assignment was conducted voluntarily by ESG Risk Assessments & Insights Limited as part of their ESG assessment process. Similar to the previous rating, the company has clarified that it did not engage the rating provider for this purpose, making it an unsolicited assessment.

Rating Methodology and Independence

ESG Risk Assessments & Insights Limited determined the rating independently based on Wockhardt's public disclosures and other publicly available information. The rating provider conducted its assessment without any direct engagement or commissioning from the company, ensuring an objective evaluation of the pharmaceutical company's ESG practices and performance.

Regulatory Compliance and Disclosure

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This regulatory framework mandates listed companies to inform exchanges about ESG ratings received from SEBI-registered providers.

The company has made this information available on its official website at www.wockhardt.com , ensuring transparency and accessibility for stakeholders. Company Secretary Rashmi Mamtura signed the regulatory filing dated January 1, 2026, with reference number WOCK/SEC/SE/2025-26/058, confirming the authenticity of the disclosure.